Research Notes
Published 8 August 2026 · Obsidian BioTech Research Team
SS-31 and MOTS-C are both grouped under "mitochondrial peptides" in research literature, which leads to some confusion — they are studied for related outcomes but work through almost entirely different mechanisms. This comparison lays out where they overlap and where they don't.
SS-31 is a small, cell-permeable tetrapeptide that concentrates in the inner mitochondrial membrane by binding cardiolipin, a phospholipid unique to that membrane. Cardiolipin is essential for organising the electron transport chain complexes that produce ATP. In preclinical models, SS-31 has been studied for its ability to stabilise cardiolipin structure, reduce mitochondrial reactive oxygen species production, and preserve ATP synthesis under stress conditions such as ischemia-reperfusion injury. Its research applications concentrate heavily on cardiac and skeletal muscle tissue, where mitochondrial density is highest.
MOTS-C is a mitochondrial-derived peptide — meaning it's encoded within mitochondrial DNA itself, in a region of the 12S rRNA gene, rather than by nuclear DNA like most peptides. Under metabolic stress, MOTS-C has been shown in research models to translocate to the cell nucleus and regulate the expression of nuclear genes involved in metabolic stress response, functioning as a retrograde signal from mitochondria back to the nucleus. It has been studied for its association with AMPK pathway activation and insulin sensitivity, and is frequently discussed in exercise physiology research as a metabolically active peptide that increases with physical activity.
| Origin | SS-31: synthetic, aromatic-cationic design |
| MOTS-C: naturally mitochondrial-DNA-encoded | |
| Primary site of action | SS-31: inner mitochondrial membrane (cardiolipin) |
| MOTS-C: cytosol and cell nucleus | |
| Research focus | SS-31: oxidative stress, ATP preservation, cardiac/muscle tissue |
| MOTS-C: metabolic regulation, insulin sensitivity, exercise response |
Both compounds are supplied as lyophilised powder and follow the same general handling principles — see our storage and reconstitution guide. As with any peptide comparison, published mechanisms come from in-vitro and preclinical models; results in one experimental system do not necessarily generalise to another.
Research Use Only
This article summarises publicly available research literature for informational purposes only. It is not medical advice. Neither SS-31 nor MOTS-C has been approved by the MHRA, FDA or any regulatory body for human or veterinary use, and both are supplied by Obsidian BioTech strictly for in-vitro laboratory research.
Related Products